摘要
目的:探讨耐多药肺结核(MDR-TB)患者血清骨桥蛋白(OPN)、高迁移率族蛋白B1(HMGB1)与T细胞亚群和化学治疗疗效的关系。方法:选择2018年3月至2021年9月徐州市传染病医院收治的147例MDR-TB患者(MDR-TB组),另选择同期徐州市传染病医院收治的109例非MDR-TB患者(对照组)。Pearson相关性分析MDR-TB组血清OPN、HMGB1与外周血T细胞亚群的相关性。多因素Logistic回归分析MDR-TB治疗未成功的因素。结果:MDR-TB组血清OPN、HMGB1与外周血CD8^(+)计数呈正相关(P<0.05),与外周血CD3^(+)计数、CD4^(+)计数、CD4^(+)/CD8^(+)比值呈负相关(P<0.05)。未成功组血清OPN、HMGB1水平高于成功组(P<0.05)。多因素Logistic回归分析结果显示空洞、高OPN、高HMGB1是MDR-TB治疗未成功的危险因素(P<0.05)。结论:MDR-TB患者血清OPN、HMGB1水平显著升高,且与T细胞亚群异常以及化学治疗未成功有关。
Objective:To investigate the relationship between serum osteopontin(OPN),high mobility group protein B1(HMGB1)and T cell subsets and chemotherapy efficacy in patients with multidrug-resistant pulmonary tuberculosis(MDR-TB).Methods:147 MDR-TB patients(MDR-TB group)admitted to Xuzhou Infectious Disease Hospital from March 2018 to September 2021 were selected,and 109 non-MDR-TB patients(control group)admitted to Xuzhou Infectious Disease Hospital during the same period were selected.The correlation between serum OPN,HMGB1 and peripheral blood T cell subsets in MDR-TB group was analyzed by Pearson correlation analysis.The factors of unsuccessful MDR-TB treatment were analyzed by multivariate Logistic regression analysis.Results:Serum OPN and HMGB1 in MDR-TB group were positively correlated with peripheral blood CD8^(+)count(P<0.05),and negatively correlated with peripheral blood CD3^(+)count,CD4^(+)count and CD4^(+)/CD8^(+)ratio(P<0.05).Multivariate Logistic regression analysis showed that cavity,high OPN and high HMGB1 were risk factors for unsuccessful MDR-TB treatment(P<0.05).Conclusion:The levels of serum OPN and HMGB1 in MDR-TB patients are significantly increase,which are relate to the abnormality of T cell subsets and the failure of chemotherapy.
作者
李萌
潘修成
彭乐
张硕
毛传春
LI Meng;PAN Xiu-cheng;PENG Le;ZHANG Shuo;MAO Chuan-chun(The First Clinical College of Xuzhou Medical University,Xuzhou,Jiangsu,221000,China;Department of Tuberculosis,Xuzhou Infectious Disease Hospital,Xuzhou,Jiangsu,221004,China;Department of Infectious Diseases,Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu,221000,China)
出处
《现代生物医学进展》
CAS
2024年第19期3758-3760,共3页
Progress in Modern Biomedicine
基金
江苏省高等学校自然科学研究面上项目(20KJD180528)。
关键词
耐多药肺结核
T细胞亚群
化学治疗
疗效
骨桥蛋白
高迁移率族蛋白B1
Multidrug-resistant pulmonary tuberculosis
T cell subsets
Chemotherapy
Efficacy
Osteopontin
High mobility group protein B1